# A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Source: https://onco.cc/trials/nct06747585/  
OnCo record `nct06747585` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ALE.P02 in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, run by Alentis Therapeutics AG, now recruiting.

## Summary

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors is a phase 1/2 interventional study registered as NCT06747585 by Alentis Therapeutics AG, with 170 participants planned, started 2024-12-16 and due to reach its primary completion in 2028-02-15. Interventions recorded: ALE.P02.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06747585
- Phase: 1/2
- Setting: A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors
- Sponsor: Alentis Therapeutics AG
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT06747585: https://clinicaltrials.gov/study/NCT06747585

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- companies: [Alentis Therapeutics](https://onco.cc/companies/alentis-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06747585.json